

• MS Therapies	• Avonex	• Rebif	• Betaseron	• Copaxone
• Injection Type	• Intramuscular (In the Muscle)	• Subcutaneous (Under the Skin)	• Subcutaneous (Under the Skin)	• Subcutaneous (Under the Skin)
• Injection Frequency	• Once a Week	• 3 Times a Week	• Every Other Day	• Every Day
• Effective After First Attack*	• Yes		• Yes	
• Patient Support	• Yes	• Yes	• Yes	• Yes
• Refrigeration Required?	• Yes	• Yes	• No	• Yes
• Reduces Flare-ups	• Yes	• Yes	• Yes	• Yes
• Slows Physical Disability*	• Yes	• Yes		
• Needle Size (Larger Gauge=Thinner Needle)	• 23-25 gauge	• 29 gauge	• 27 gauge	• 27 gauge

*Currently:

1. Studies have not been completed to show whether Rebif is effective after the first attack; however, studies have shown that Rebif is safe and effective in long-term use.
2. Studies have shown that Betaseron reduces flare-ups, but studies have not been completed to show that Betaseron slows physical disability
3. Studies have not been completed to show whether Copaxone is effective after the first attack, nor have they been completed to show that Copaxone slows physical disability, although it has shown that Copaxone reduces flare-ups.

Works Cited

"Avonex: Everyday Empowerment." Avonex. Biogen Idec. 15 July 2008

<<http://www.avonex.com>>.

"Betaseron: MS Doesn't Wait. Neither Should You." Betaseron. 2007. Bayer Healthcare

Pharmaceuticals Inc. 15 July 2008 <<http://www.betaseron.com>>.

"Copaxone." Copaxone. 2008. Teva Pharmaceutical Industries Ltd. 15 July 2008

<<http://www.copaxone.com>>.

"MS Lifelines: Offering MS Education and Support." Rebif/MS Lifelines. EMD Serano,

Inc. and Pfizer Inc. 15 July 2008 <<http://www.rebif.com>>.